2025-05-05 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Report

**0. Executive Summary:**

Eli Lilly and Co. (LLY) is a leading pharmaceutical company.  Its stock has significantly outperformed the S&P 500 (VOO) over the analyzed period, showing robust growth and profitability. However, recent price action suggests potential short-term volatility.  Long-term prospects remain positive, based on strong financial performance and high expected returns.

**1. Performance Comparison & Alpha/Beta Analysis:**

LLY has shown a cumulative return of 322.13%, significantly outperforming the S&P 500's 82.57% return.  The current divergence (239.6) represents 72.9% of the historical range, indicating a substantial outperformance relative to its past performance compared to the S&P 500.

The Alpha/Beta analysis reveals consistently positive alpha values across the analyzed periods (2015-2025), indicating consistent outperformance against the market benchmark.  The Beta values are also consistently high (above 0.1) indicating higher volatility compared to the market, and increasing market capitalization (Cap(B)) suggests significant growth of the company. However, high Beta suggests higher risk.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 14.0% | 55.9% | -19.0% | 0.1 | 67.7 |
| 2016-2018  | 42.0% | 58.6% | 21.0% | 0.1 | 95.1 |
| 2017-2019  | 55.0% | 58.6% | 21.0% | 1.4 | 110.4 |
| 2018-2020  | 57.0% | 58.6% | 27.0% | 0.7 | 144.7 |
| 2019-2021  | 116.0% | 60.5% | 55.0% | 0.4 | 240.3 |
| 2020-2022  | 111.0% | 64.9% | 102.0% | 0.3 | 322.6 |
| 2021-2023  | 152.0% | 64.9% | 132.0% | 0.3 | 519.2 |
| 2022-2024  | 171.0% | 72.1% | 150.0% | 0.3 | 692.0 |
| 2023-2025  | 154.0% | 76.8% | 133.0% | 0.2 | 772.0 |


**2. Recent Price Action:**

* **Closing Price:** $859.73
* **Last Market:** $823.62 (+$3.72 from previous close)  This represents a modest increase.
* **5-Day Moving Average:** $834.93
* **20-Day Moving Average:** $784.95
* **60-Day Moving Average:** $833.62

The price is above both the 20-day and 60-day moving averages, suggesting an upward trend, although the recent price action shows some consolidation.


**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.4053 (Medium Risk)
* **RSI:** 59.94 (Slightly above neutral; not overbought)
* **PPO:** 1.75 (Positive, indicating upward momentum)
* **20-Day Relative Divergence Change:** +4.1 (Short-term upward trend)
* **Expected Return:** 76.3% (over S&P 500 over 2+ years with long-term investment)  This signifies a very high expected excess return compared to the S&P 500.

The recent price increase of $3.72 is not a significant jump to warrant the label of "rapid increase" (though it is a positive sign).


**4. Recent Earnings Analysis:**

The earnings data shows some volatility, but generally positive trends in both EPS and revenue.  There's a notable jump in EPS in Q1 2025, and consistent growth in Revenue.  The duplicated 2025-05-01 data point needs clarification.


| Date       | EPS  | Revenue       |
|------------|------|----------------|
| 2025-05-01 | 3.07 | $12.73B        |
| 2024-10-30 | 1.08 | $11.44B        |
| 2024-08-08 | 3.29 | $11.30B        |
| 2024-04-30 | 2.49 | $8.77B         |
| 2025-05-01 | 2.49 | $8.77B         |


**5. Financial Information:**

Revenue shows strong and relatively consistent growth, although there's a slight dip in Q2 2024. Profit margins remain consistently high, above 80%. Equity has shown steady growth, and ROE fluctuates but remains generally high, indicating strong profitability.

Revenue and Profitability:

| Quarter      | Revenue     | Profit Margin |
|--------------|-------------|---------------|
| 2025-03-31  | $12.73B     | 82.53%        |
| 2024-12-31  | $13.53B     | 82.24%        |
| 2024-09-30  | $11.44B     | 81.02%        |
| 2024-06-30  | $11.30B     | 80.80%        |
| 2024-03-31  | $8.77B      | 80.91%        |


Capital and Profitability:

| Quarter      | Equity      | ROE           |
|--------------|-------------|---------------|
| 2025-03-31  | $15.76B     | 17.50%        |
| 2024-12-31  | $14.19B     | 31.07%        |
| 2024-09-30  | $14.24B     | 6.81%         |
| 2024-06-30  | $13.56B     | 21.88%        |
| 2024-03-31  | $12.81B     | 17.51%        |


**6. Overall Conclusion:**

LLY exhibits strong historical and projected performance, significantly outperforming the S&P 500.  The high expected return and generally positive financial indicators suggest a promising long-term investment opportunity. However, investors should be aware of the higher volatility (reflected in the Beta) and consider the medium risk level indicated by the MRI.  Further investigation into the duplicated data point in the earnings report is recommended. The strong upward trend supported by moving averages and positive momentum indicators suggest positive short-term outlook as well, however, close monitoring of the price action is advised.
